Checkpoint Inhibitor (PD-1/PD-L1) Deal Benchmarks

Median Upfront

$266M

Range: $148M - $376M

Total Deal Value

$1.7B

Range: $1.1B - $2.3B

Royalty Rate

11.9% - 19.5%

Tiered up to 23.5%

Dev Milestones

$355M

Range: $237M - $475M

Model Your Deal

Market Analysis

Checkpoint inhibitor licensing in 2026 is characterized by market maturation, biosimilar pressure on first-generation PD-1/PD-L1 agents, and sustained demand for differentiated IO-combination assets. Phase 2 monoclonal antibody deals in the IO space carry a median total deal value of $1.7B, with upfront payments between $148M and $376M. Novel checkpoint targets (LAG-3, TIGIT, CD47) and bispecific IO constructs command premiums over follow-on PD-1 agents.

IO deal structures are milestone-heavy with development milestones averaging $355M, reflecting the need for combination trial data in registrational settings. Regulatory milestones of $568M and commercial milestones of $497M complete the typical IO deal. The 16% upfront / 84% milestone split reflects the clinical risk and competitive density of the IO landscape.

Royalty rates for checkpoint inhibitor deals range from 11.9% to 19.5% at the base tier, with tiered escalation to 23.5%. Biosimilar competition for pembrolizumab and nivolumab is compressing royalties for undifferentiated PD-1 agents, while next-generation IO mechanisms and tumor-specific conditional activation platforms maintain premium royalty structures.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

Is the checkpoint inhibitor deal market saturated?

While the PD-1/PD-L1 space is mature, deal activity continues for differentiated assets. Undifferentiated follow-on PD-1 antibodies face compressed terms, but novel IO combinations, bispecific checkpoint constructs, and next-generation targets (LAG-3, TIGIT, CD47, NKG2A) maintain premium deal values averaging $1.7B at Phase 2.

How are IO combination therapy licensing deals structured?

IO combination deals are characterized by higher total deal values than monotherapy IO assets due to the broader indication potential. Combination-specific milestones are common, with separate triggers for each indication-specific registration trial. Development milestones average $355M, and cross-indication expansion milestones can add 20-40% to total deal value.

What is the biosimilar impact on checkpoint inhibitor deal valuations?

The impending LOE for pembrolizumab (2028) and nivolumab is reshaping IO deal economics. Biosimilar-referenced PD-1 agents face significant valuation discounts, while differentiated IO assets with novel mechanisms or superior safety profiles maintain premium terms. Licensors increasingly require superiority data versus PD-1 backbone therapy to justify premium deal terms.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating

Checkpoint Inhibitor (PD-1/PD-L1) Deal Benchmarks

Market Analysis

Full Benchmark Analysis

Customize these benchmarks for your asset

Frequently Asked Questions

Full Benchmark Analysis

Related Benchmarks

ADC Deal Benchmarks

Bispecific Antibody Deals

Oncology Deal Overview 2026

NSCLC Deal Benchmarks

Ready to Calculate Your Deal Terms?